Top Page
Oncopeptides AB
(ONCO)
Oncopeptides AB (ONCO) vs. iShares MSCI Sweden ETF (EWD)
Oncopeptides AB Business Overview & Revenue Model
Oncopeptides AB Earnings Call Summary
Oncopeptides AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.87M | 31.65M | 35.22M | 8.36M | 118.30M | 0.00 |
| Gross Profit | 49.13M | 28.98M | 36.30M | 8.35M | 65.17M | -14.40M |
| EBITDA | -260.65M | -261.81M | -231.62M | -319.62M | -1.40B | -1.58B |
| Net Income | -267.18M | -284.61M | -249.11M | -337.95M | -1.43B | -1.59B |
Balance Sheet | ||||||
| Total Assets | 136.44M | 244.19M | 238.38M | 385.32M | 439.38M | 946.76M |
| Cash, Cash Equivalents and Short-Term Investments | 70.15M | 178.54M | 173.44M | 344.51M | 364.30M | 852.48M |
| Total Debt | 124.23M | 141.72M | 126.16M | 9.54M | 14.19M | 19.36M |
| Total Liabilities | 203.32M | 189.91M | 181.60M | 91.03M | 228.51M | 369.86M |
| Stockholders Equity | -66.88M | 54.28M | 56.78M | 294.29M | 210.87M | 576.90M |
Cash Flow | ||||||
| Free Cash Flow | -324.71M | -260.57M | -279.61M | -423.02M | -1.52B | -1.31B |
| Operating Cash Flow | -324.71M | -260.57M | -279.49M | -420.51M | -1.52B | -1.30B |
| Investing Cash Flow | 496.00K | 496.00K | -116.00K | -2.51M | -339.00K | -20.13M |
| Financing Cash Flow | 11.91M | 263.81M | 106.89M | 392.40M | 1.03B | 1.32B |
Oncopeptides AB Technical Analysis
Oncopeptides AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr1.38B | ― | ― | ― | 131.20% | 32.28% | |
48 Neutral | €217.39M | 1.17 | -16.90% | ― | 4.64% | ― | |
47 Neutral | €1.04B | -3.56 | -35.03% | ― | ― | 25.14% | |
43 Neutral | €390.59M | -2.68 | -79.60% | ― | ― | 31.62% | |
32 Underperform | €97.31M | -1.80 | -1291.15% | ― | ― | 28.54% | |
31 Underperform | €815.45M | -4.15 | 81.19% | ― | ― | ― |
Oncopeptides AB Corporate Events
Oncopeptides AB has announced the formation of its Nomination Committee for the 2026 annual general meeting. The committee comprises representatives from the company’s three largest shareholders by voting rights, as well as the Chairman of the Board. This development is significant for Oncopeptides as it ensures shareholder representation in the decision-making process, potentially impacting the company’s strategic direction and governance. The committee’s proposals will be shared in the notice for the annual general meeting and on the company’s website.
Oncopeptides AB announced that a panel of multiple myeloma experts has endorsed the use of its drug Pepaxti, also known as melflufen, for treating relapsed, refractory multiple myeloma. The expert consensus, published in the Annals of Hematology, emphasizes Pepaxti’s effectiveness for heavily pretreated patients, including the elderly and those with high-risk disease profiles, reinforcing its role as a critical treatment option. This endorsement strengthens Pepaxti’s market positioning and confirms its utility across diverse patient subgroups, aligning with findings from pivotal studies and real-world applications.
Oncopeptides AB reported a significant growth in net sales for Q3 2025, with a 174% increase year over year, driven by its key European markets. The company is progressing towards becoming cash flow positive by the end of 2026 and is in negotiations with potential partners in Japan. The period also saw the oversubscription of a rights issue and the inclusion of their drug Pepaxti in European guidelines, which could enhance their market positioning and stakeholder confidence.
Oncopeptides AB announced that a collaborative study on NK cell engagers, part of the Eurostars NKENGAGE project, will be presented at the American Society of Hematology Annual Meeting. The study explores a novel immunotherapeutic approach for multiple myeloma using NK cells, showing promising preclinical results with reduced toxicity compared to T-cell strategies. This recognition at ASH highlights Oncopeptides’ expansion beyond peptide-drug conjugates and its potential to address unmet needs in cancer treatment.
Oncopeptides AB announced a change in the number of votes due to the conversion of class C shares to ordinary shares as part of its incentive program. This adjustment reflects the company’s ongoing efforts to align its share structure with its strategic goals, potentially impacting its market positioning and shareholder value.
Oncopeptides AB announced the upcoming release of its Q3 2025 financial report, scheduled for November 5, 2025. The company will host a webcast and Q&A session for investors, analysts, and media, led by CEO Sofia Heigis and CFO Henrik Bergentoft. This event provides stakeholders with insights into the company’s financial performance and strategic direction, potentially impacting its market positioning.
Oncopeptides AB announced it will host a Capital Markets Update on November 13, 2025, to provide insights into its strategic direction and expanding role in the treatment of multiple myeloma. The event will feature presentations from international experts and company leaders, offering clinical, scientific, and market perspectives, which may influence the company’s market positioning and investment appeal.
Oncopeptides AB announced the publication of three case reports in the Journal of Cancer Research and Clinical Oncology, showcasing long-lasting responses to their drug Pepaxti in patients with relapsed or refractory multiple myeloma. These findings, derived from the OCEAN and HORIZON studies, highlight Pepaxti’s potential as a significant treatment option for patients who may not have access to novel immunotherapies, demonstrating its ability to deliver sustained benefits and durable remissions in real-world settings.
Oncopeptides AB has issued warrants to fulfill its obligations under a loan agreement with the European Investment Bank (EIB). This move involves a total of 2,788,416 warrants entitling the EIB to 3,383,326 ordinary shares, which will increase the company’s share capital by approximately SEK 375,925.13. The decision, authorized by the board of directors, allows Oncopeptides to meet its contractual obligations and potentially strengthens its financial position, impacting its operations and stakeholder interests.
Oncopeptides AB has announced a change in the number of shares and votes following a rights issue, which concluded on September 15, 2025. The total number of shares now stands at 272,706,357, with a share capital increase of SEK 5,216,392.878513. This change reflects the company’s ongoing financial adjustments to support its operations and strategic goals in the biotech industry.
Oncopeptides AB announced the successful completion of its rights issue, which was oversubscribed by approximately 157 percent, raising around SEK 150 million. This financial boost is expected to enhance the company’s operational capabilities and strengthen its market position, with new shares set to begin trading on Nasdaq Stockholm by late September 2025.